Bioasis Technologies Inc. V.BTI

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

TSXV:BTI - Post by User

Bioasis Technologies Inc. > Midatech at $1.0475

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Dec 31, 2022 5:04pm

68 Views

Post# 35198679

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475

KayakerBC wrote: So the higher the Midatech stock price goes up from here to the closing of the arrangement the better.

I doubt it will go up too much (unless BTI does too). As the closing gets closer I would expect there to be less arbitrage opportunity.

"My understanding: If, for example, you have 10,000 BTI shares, upon closing, that gets converted to 9556 "Ordinary Shares" in the form of American Depositary Shares (ADS), rounded down to the nearest whole ADS. Each ADS represents 25 Ordinary Shares. So that 9556 Ordinary Shares becomes 382.24 (round down) to 382 ADS in Biodexa Therapeutics."

KBC (final question) Is this conversation formula fixed between now and the closing of the agreement? Or will there be a recalibration at some point?

G1945V

<< Previous

Bullboard Posts

Next >>

What is the gold outlook for the rest of 2024?